Market LIVE
Published markets; coverage varies by country
Product profile · United States

PROGRAF

 ·  Patent Litigation & Settlement History ↓

IngredientTACROLIMUS
Application typeNDA
Application210115
Product002
Dosage formFOR SUSPENSION
RouteORAL
StrengthEQ 1MG BASE/PACKET
Approval date2018-05-24
Marketing statusPrescription
Status event—
ApplicantASTELLAS
Product source

Current GenericRadar decision

Year2025
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeREGULATORY_EXCLUSIVITY
Anchor date2025-05-24
Patent anchor—
Exclusivity anchor2025-05-24
Protection date2028-07-16
First Final ANDA—
Status event—

Exact oral granules operational pediatric dosing scope: kidney/heart/liver ODE to 2025-05-24 combined with lung ODE to 2028-07-16. The joint coverage date is 2025-05-24; lung alone does not cover all transplant organs. Other tacrolimus routes and prolonged-release products are not imported.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
GNR_FULL_SCOPE2018-05-242025-05-24Granules for oral suspension: pediatric kidney, liver, heart and lung transplant prophylaxis.YY2025-05-24Source
ODE-360—2028-07-16FOR PROPHYLAXIS OF ORGAN REJECTION IN ADULT AND PEDIATRIC PATIENTS RECEIVING ALLOGENEIC LUNG TRANSPLANTNN——Source
ODE-3602021-07-162028-07-16FOR PROPHYLAXIS OF ORGAN REJECTION IN ADULT AND PEDIATRIC PATIENTS RECEIVING ALLOGENEIC LUNG TRANSPLANTNN——Source

2026-10-13 · HISTORICAL_RECORDS_RECOVERED · Historical coverage: ANNUALS_AND_MONTHLY_REVIEWED

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (3)
TypeDateRoleBasisSource
REGULATORY_EXCLUSIVITY—SCOPE_CONTEXTFOR PROPHYLAXIS OF ORGAN REJECTION IN ADULT AND PEDIATRIC PATIENTS RECEIVING ALLOGENEIC LUNG TRANSPLANTSource
REGULATORY_EXCLUSIVITY2025-05-24CANONICAL_ANCHORGranules for oral suspension: pediatric kidney, liver, heart and lung transplant prophylaxis.Source
REGULATORY_STATUS2025-05-24CANONICAL_DECISIONExact oral granules operational pediatric dosing scope: kidney/heart/liver ODE to 2025-05-24 combined with lung ODE to 2028-07-16. The joint coverage date is 2025-05-24; lung alone does not cover all transplant organs. Other tacrolimus routes and prolonged-release products are not imported.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.